跳到正文
原文
Endpoints News 生物医药· Max Gelman·· 2026-10-08AI 评分44

Zealand与Roche发布amylin药物肥胖和糖尿病II期研究初步结果,Lilly仍是障碍

Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle

AI 导读

Zealand Pharma与Roche公布其amylin药物在肥胖和糖尿病治疗中的II期中期数据,旨在与Eli Lilly竞争。尽管数据显示潜力,但Lilly在此领域占据主导地位,构成主要竞争障碍。该研究结果目前处于初步阶段,尚未最终确证。

正文

Zealand Phar­ma and Roche rolled out some mid-stage da­ta for their amylin drug in obe­si­ty and di­a­betes, hop­ing to com­pete with Eli Lil­ly.

In a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news